Evaluation of a new continuous mononuclear cell collection procedure in a single transplant center cohort enriched for AL amyloidosis patients.
暂无分享,去创建一个
S. Sarosiek | V. Sanchorawala | J. Sloan | K. Quillen | Anita Pudusseri | A. Shelton | D. Sarnacki | D. Brauneis | India Smith | Diane Sarnacki | Shayna R Sarosiek
[1] R. Costello,et al. Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures , 2017, Journal of clinical apheresis.
[2] E. Scott,et al. Continuous CD34+ cell collection by a new device is safe and more efficient than by a standard collection procedure: results of a two‐center, crossover, randomized trial , 2016, Transfusion.
[3] D. Seldin,et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. , 2015, Blood.
[4] D. Seldin,et al. Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[5] B. Griffiths,et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. , 2014, JAMA.
[6] G. Doros,et al. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement , 2014, Bone Marrow Transplantation.
[7] J. Wingard,et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. , 2013, Blood.
[8] M. Skinner,et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. , 2012, Blood.
[9] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] E. Jantunen,et al. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens , 2011, Bone Marrow Transplantation.
[11] F. Jardin,et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. , 2007, The New England journal of medicine.
[12] G. Merlini,et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. , 2006, Blood.
[13] M. Skinner,et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. , 2003, Kidney international.
[14] S. Leitman,et al. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. , 2002, Blood.
[15] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .